全文获取类型
收费全文 | 252篇 |
免费 | 26篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 31篇 |
口腔科学 | 13篇 |
临床医学 | 29篇 |
内科学 | 66篇 |
皮肤病学 | 11篇 |
神经病学 | 12篇 |
特种医学 | 8篇 |
外科学 | 33篇 |
综合类 | 20篇 |
预防医学 | 7篇 |
眼科学 | 8篇 |
药学 | 28篇 |
中国医学 | 1篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 23篇 |
2021年 | 49篇 |
2020年 | 33篇 |
2019年 | 13篇 |
2018年 | 26篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 15篇 |
2014年 | 14篇 |
2013年 | 10篇 |
2012年 | 25篇 |
2011年 | 16篇 |
2010年 | 8篇 |
2009年 | 4篇 |
2008年 | 3篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 3篇 |
排序方式: 共有279条查询结果,搜索用时 15 毫秒
261.
Yazed S. Alruthia Monira Alwhaibi Mashal F. Alotaibi Shatha A. Asiri Bushra M. Alghamdi Ghadah S. Almuaythir Wejdan R. Alsharif Hala H. Alrasheed Yahya A. Alswayeh Abdulaziz J. Alotaibi Mohammad Almeshal Saleh N. Aldekhail Abdulrahman Alhusaini Sulaiman A. Alrashed Ali M. Alrumaih Mohammed A. Dahhas Mohammed A. Alghamdi Mohammad S. Aleheidib Aws Alshamsan 《Saudi Pharmaceutical Journal》2018,26(7):947-951
Drug shortages are a multifaceted problem that has been recurring in Saudi Arabia over the past decade with its significant negative impact on patient care. However, there is a dearth of evidence about possible domestic reasons, if any, behind this recurring problem. Recently, the Pharmacy Education Unit at King Saud University College of Pharmacy has called for a meeting with multiple stakeholders from academia, pharmaceutical care, pharmaceutical industry, purchasing and planning, and regulatory bodies to unveil the root domestic causes of the drug shortages in the Kingdom. Four major topics were used to guide the discussion in this meeting, including: current situation of drug shortages in Saudi Arabia, major factors contributing to drug shortages, challenges and obstacles to improve drug supply, and stakeholders’ recommendations to manage drug shortages. The meeting was audio-recorded and transcribed into verbatim by five authors. The text was then reviewed and analyzed to identify different themes by the first and third authors. Multiple causes were identified and several recommendations were proposed. The main domestic causes of drug shortages that were explored in this study included poor medication supply chain management, lack of government regulation that mandates early notification of drug shortages, a government procurement policy that does not keep pace with the changes in the pharmaceutical market, low profit margins of some essential drugs, weak and ineffective law-violation penalties against pharmaceutical companies and licensed drug importers and distributors, and overdependence on drug imports. The participants have also proposed multiple recommendations to address drug shortages. Policy makers should consider these factors that contribute to drug shortages in Saudi Arabia as well as the recommendations when designing future initiatives and interventions to prevent drug shortages. 相似文献
262.
Khalid M. Alkharfy Amal M. Alghamdi Khawla M. Bagulb Fahad I. Al-Jenoobi Abdullah M. Al-Mohizea Saleh Al-Muhsen Rabih Halwani Mohammad K. Parvez Mohammed S. Al-Dosari 《Archives of Medical Science》2013,9(4):731-738
Introduction
Glucuronidation is an important phase II pathway responsible for the metabolism of many endogenous substances and drugs to less toxic metabolites, which undergo renal excretion. The aim of the current work was to evaluate genotype and allele frequencies of certain UDP-glucuronosyltransferase 1A1 (UGT1A1) variants in an Arab population.Material and methods
Genomic DNA was isolated from 192 healthy unrelated Saudi males of various geographic regions and genotyping of UGT1A1*6, *27, *36, *28, *37, and *60 was carried out using polymerase chain reaction (PCR) amplification followed by direct sequencing.Results
The most common allele for (TA) repeats was the wild type (TA)6 with a frequency of 74.3% followed by the mutant (TA)7 (i.e., UGT1A1*28) with a frequency of 25.7%. The distribution of UGT1A1*60 allele was 62.4% among subjects with the homozygous mutant genotype of 35.4%, while the wild type variant represents 10.6% only. Both UGT1A1*6 and *27 were not detected as all screened subjects showed a homozygous wild type pattern. Similarly, UGT1A1*36* and *37 were either not present or rarely found, respectively. In comparison to other populations, the frequency of UGT1A1*60 and *28 in the studied population was less than that of African Americans but higher than Asians. The geographical origin of the study subjects also implied some differences in genotype distribution of (TA) repeats and UGT1A1*60.Conclusions
Our data indicate that Saudis harbor some important UGT1A1 mutations known to affect enzyme activity. Additional studies are warranted to assess the clinical implications of these gene polymorphisms in this ethnic group. 相似文献263.
Mohammed Y. Hasosah Suzane Y. Kutbi Abdulfattah W. Al-Amri Ashraf F. Alsahafi Ghassan A. Sukkar Khaled J. Alghamdi Kevan Jacobson 《Saudi Journal Of Gastroenterology》2012,18(3):208-213
Background/Aim:
Cytomegalovirus (CMV) is the most common congenital viral infection, occurring in 0.4%–2.3% of all live births. The clinical manifestations of CMV are multiorgan involvement. Currently, the numbers of studies of hepatic CMV infection in immunocompetent infants are insufficient and little information exists in the medical literature about the hepatic manifestations and complications of CMV.Patients and Methods:
Nine infants diagnosed with hepatic CMV infection were included in the study. The diagnosis was based on the presence of IgM anti-CMV antibodies titer in serum and detection of CMV-DNA in blood. The authors identified clinical characteristics, biochemical characteristics, immunologic markers, and the outcome of hepatic CMV with or without treatment.Results:
Jaundice was the most common clinical feature of CMV infection in infancy (100%). Hepatic abnormalities in the form of cholestasis (defined as a serum conjugated bilirubin concentration greater than 17.1 μmol/L or greater than 20% of the total serum bilirubin) were found in all patients (100%), hepatitis (77%), hypoalbuminemia (55%), elevated alkaline phosphatase, and gamma-glutamyltransferase (77%). Other findings showed hepatosplenomegaly (44%), thrombocytopenia (22%) and low birth weight (11%) The treatment of hepatic CMV infection was indicated in 66% and was not indicated in 33%. Both of them had resolved cholestasis and hepatitis.Conclusion:
Jaundice and cholestasis were the most common clinical features of hepatic CMV infections. Hepatic CMV infection in young infants is often a self-limited illness that does not require antiviral therapy. Most of the patients with hepatic CMV infection had a favorable outcome. 相似文献264.
Aswin Hari Anutosh Ganguly Libing Mu Shevaun P. Davis Melanie D. Stenner Raymond Lam Fay Munro Inana Namet Enaam Alghamdi Tobias Fürstenhaupt Wei Dong Pascal Detampel Lian Jun Shen Matthias W. Amrein Robin M. Yates Yan Shi 《European journal of immunology》2015,45(2):383-395
Peptides presented by MHC class I molecules are mostly derived from proteins synthesized by the antigen‐presenting cell itself, while peptides presented by MHC class II molecules are predominantly from materials acquired by endocytosis. External antigens can also be presented by MHC class I molecules in a process referred to as cross‐presentation. Here, we report that mouse dendritic cell (DC) engagement to a phagocytic target alters endocytic processing and inhibits the proteolytic activities. During phagocytosis, endosome maturation is delayed, shows less progression toward the lysosome, and the endocytosed soluble antigen is targeted for MHC class I cross‐presentation. The antigen processing in these arrested endosomes is under the control of NAPDH oxidase associated ROS. We also show that cathepsin S is responsible for the generation of the MHC class I epitope. Taken together, our results suggest that in addition to solid structure uptake, DC phagocytosis simultaneously modifies the kinetics of endosomal trafficking and maturation. As a consequence, external soluble antigens are targeted into the MHC class I cross‐presentation pathway. 相似文献
265.
Omamah Alfarisi Wael A. Alghamdi Mohammad H. Al-Shaer Charles A. Peloquin 《Expert review of clinical pharmacology》2017,10(10):1027-1036
Introduction: One-third of the world’s population is infected with Mycobacterium tuberculosis (M.tb.). Latent tuberculosis infection (LTBI) can progress to tuberculosis disease, the leading cause of death by infection. Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb. What are the advantages of each for LTBI or tuberculosis treatment?Areas covered: We review studies assessing the pharmacokinetics (PK), pharmacodynamics (PD), drug interaction risk, safety, and efficacy of rifampin and rifapentine and provide basis for comparing them.Expert commentary: Rifampin has shorter half-life, higher MIC against M.tb, lower protein binding, and better distribution into cavitary contents than rifapentine. Drug interactions for the two drugs maybe similar in magnitude. For LTBI, rifapentine is effective as convenient, once-weekly, 12-week course of treatment. Rifampin is also effective for LTBI, but must be given daily for four months, therefore, drug interactions are more problematic. For drug-sensitive tuberculosis disease, rifampin remains the standard of care. Safety profile of rifampin is better-described; adverse events differ somewhat for the two drugs. The registered once-weekly rifapentine regimen is inadequate, but higher doses of either drugs may shorten the treatment duration required for effective management of TB. Results of clinical trials evaluating high-dose rifamycin regimens are eagerly awaited. 相似文献
266.
267.
268.
Abdullah A. Alghamdi M.Sc. M.D. Steve K. Singh M.D. Barbara C. S. Hamilton M.Mus. Mrinal Yadava M.B.B.S. Helen Holtby M.D. Glen S. Van Arsdell M.D. Osman O. Al‐Radi M.D. 《Journal of cardiac surgery》2010,25(5):586-595
Abstract Objective: To derive evidence‐based recommendations regarding early extubation strategy after congenital cardiac surgery. Outcomes: Incidence of total mortality, morbidity, reintubation, length, and costs of intensive care unit and hospital stay. Evidence: Medline, Embase, and the Cochrane‐controlled trial register on the Cochrane library were searched from the earliest achievable date of each database to present. No language restrictions were applied. Retrieved reprints were evaluated according to a priori inclusion criteria, and those included were critically appraised using established internal validity criteria. Benefits and Harms: Early extubation (in the operating room or ≤6 hours after surgery) was associated with a lower early mortality. There was a trend toward lower ICU and hospital length of stays, lower hospital costs, and less respiratory morbidity. There was no difference in the rate of reintubation in those extubated early versus late. Conclusion: Early extubation appears safe and is associated with reduction in length of ICU and hospital stay without adverse effects on mortality or morbidity. However, studies to date are poor, heterogeneous, and not suitable to determine a causal effect. Therefore, there is need for a well‐designed randomized clinical trial to demonstrate the potential significant benefits of early extubation . (J Card Surg 2010;25:586‐595) 相似文献
269.
270.